High dose calcitriol may reduce thrombosis in cancer patients
Authors: Beer, Tomasz M.1; Venner, Peter M.2; Ryan, Christopher W.1; Petrylak, Daniel P.3; Chatta, Gurkamal4; Dean Ruether, J.5; Chi, Kim N.6; Curd, John G.7; DeLoughery, Thomas G.1
Source: British Journal of Haematology, Volume 135, Number 3, November 2006 , pp. 392-394(3)
Publisher: Blackwell Publishing
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Summary The incidence of venous and arterial thrombosis in a placebo-controlled randomised trial of DN-101 (high dose calcitriol) with docetaxel versus docetaxel was compared. Of the 13 thrombotic events observed in the 250 patients enroled in this study, two occurred in DN-101 and 11 in placebo-treated patients (P = 0·01). This difference remained significant after adjustment for baseline history of thrombosis, atrial fibrillation and use of anti-thrombotic agents. In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans.Keywords: calcitriol; vitamin D; thrombosis; prostate cancer; thromboembolism
Document Type: Research article
DOI: 10.1111/j.1365-2141.2006.06322.x
Affiliations: 1: Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA 2: Cross Cancer Institute, Edmonton, AB, Canada 3: Columbia Presbyterian Medical Center, New York, NY 4: Pavillion Hellman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA 5: Tom Baker Cancer Centre, Calgary, AB, Canada 6: University of British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, Canada 7: Novacea, Inc, South San Francisco, CA, USA
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help